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Abstract 
Class II Major Histocompatibility complex (MHC-II) is a polymorphic heterodimer 
that binds antigen-derived peptides and presents them on the surface of antigen 
presenting cells. This mechanism of antigen presentation leads to recognition by CD4 
T-cells and T-cell activation, making it a critical element of adaptive immune 
response.  For this reason, the structural determinants of MHC-II function have been 
of great interest for the past 30 years, resulting in a robust structural understanding 
of the extracellular regions of the complex.  However, the membrane-localized 
regions have also been strongly implicated in protein-protein and protein-lipid 
interactions that facilitate Class II assembly, transport and function, and it is these 
regions that are the focus of this review.  Here we describe studies that reveal the 
strong and selective interactions between the transmembrane domains of the MHC , 
 and invariant chains which, when altered, have broad reaching impacts on antigen 
presentation and Class II function.  We also summarize work that clearly 
demonstrates the link between membrane lipid composition (particularly the 
presence of cholesterol) and MHC-II conformation, subsequent peptide binding, and 
downstream T-cell activation. We have integrated these studies into a comprehensive 
view of Class II transmembrane domain biology. 
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Abbreviations 
MHC-II: Class II Major Histocompatibility complex  
HLA:   human leukocyte antigen  
APC:  antigen presenting cell 
PM:  plasma membrane 
ER:  endoplasmic reticulum 
Ii:  Class II-associated invariant chain 
CLIP:  class-II-associated invariant chain peptide 
TCR:  T-cell receptor  
TMD:  transmembrane domain 
FTIR:  Fourier transform infrared  
MD:  molecular dynamics  
BCR:  B cell receptor  
p-MHC II: peptide-Class II complex  
CRAC:  cholesterol recognition/interaction amino acid consensus sequence 
CCM:  cholesterol consensus motif 
LD:  Leishmania donovani 
SPR:  surface plasmon resonance  
mAb:  monoclonal antibody  
DPPC:  1,2 dipalmitoyl-sn-glycero-3-phosphocholine  
DPC:  n-dodecylphosphocholine 
PBD:  peptide binding domain  
LACK:  Leishmania homolog for the receptor of activated C Kinase  
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Introduction 
 The Class II Major Histocompatibility complex (MHC-II), encoded by the 
human leukocyte antigen (HLA) gene complex in humans, is a polymorphic 
heterodimer composed of two type I membrane glycoproteins, known as the alpha 
() chain and the beta () chain.  The  and  chains of MHC-II are encoded by three 
different loci in humans to produce three different types of Class II complex termed 
HLA-DR, HLA-DQ, and HLA-DP.  These proteins have roughly 70% sequence similarity 
to one another, but display varying rates of polymorphism to generate an exceptional 
number of alleles.  Infectious disease is thought to act as one of the main driving forces 
for MHC polymorphism, promoting a large diversity of MHC proteins in the 
population.   
 MHC-II binds antigen-derived peptides produced via protease or hydrolase 
degradation of exogenous proteins, and presents them on the surface of specialized 
antigen presenting cells (APCs) such as B cells, macrophages, and dendritic cells.  
MHC-facilitated peptide presentation on the surface of APCs leads to recognition by 
CD4 T-cells, subsequent T-cell activation, and elicitation of an immune response. 
Failure of Class II-directed T-cell activation, either via mutation to create a large 
number of known alleles or severe up- or down-regulation of Class II molecules, is 
implicated in autoimmune diseases such as rheumatoid arthritis[1], type I 
diabetes[2], and multiple sclerosis[2], as well as in HIV[3], asthma[4], certain 
cancers[5], and infectious diseases[6]. These examples highlight the importance of 
correct transport of peptide-loaded Class II molecules to the surface of APCs. 
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Current models of MHC-II Assembly 
 MHC-II is transported to the plasma membrane (PM) from the site of 
biosynthesis in the endoplasmic reticulum (ER) via the endosomal transport 
pathway[7, 8].  This transport is initiated by a chaperone protein called the MHC Class 
II-associated invariant chain (Ii, also known as the Class II gamma chain or CD74), which 
is a homotrimeric type II membrane protein.  In the classical model of Class II assembly 
and transport, it is thought that Ii trimers bind three MHC-II alpha/beta heterodimers 
(, Figure 1A) to form a nine-chain Ii3(3complex.  Formation of this complex 
involves direct interaction of the CLIP (class-II-associated invariant chain peptide, 
residues 81-104) region in Ii with the Class II peptide binding cleft, blocking binding 
of self-peptides [9].Class II binding also shields the R-X-R ER retention motif present 
on the N-terminus of Ii.  It has been shown that the cytoplasmic tail of the Class II -
chain is specifically required to overcome ER retention[10], however the length of 
this tail can be as short as three amino acids (ruling out steric hindrance as a likely 
mechanism)[11].  
 The nonameric model has been challenged recently by Koch and coworkers, 
who report evidence that each Ii trimer binds a single heterodimer to form a 
Ii3pentamer (Figure 1B)[12]. Regardless of the stoichiometry, it is well-accepted 
that correct transport of the MHC-II from the ER to the PM requires binding of Ii, 
which directs the complex either to early endosomes or to the PM where it is 
internalized into clathrin-coated pits before reaching the MHC-II-rich compartment 
(MIIC)[7]. Ii is eventually degraded by proteases in endosomal compartments before 
Class II is loaded with antigenic peptide[13, 14]. 
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The structural determinants of Class II Ii//complex formation have been 
the subject of great interest for the past three decades. It has been shown that 
formation of the Ii trimer is stabilized through protein-protein interactions in its C-
terminal (luminal) domain involving residues 118-192, and that this region forms 
stable trimers in isolation[15].  Nuclear magnetic resonance (NMR) structural data 
were used to confirm the trimeric structure of a protein derived from this region[16], 
and by the late 1990s this region became known as the “trimerization” domain.  
Deletion of this luminal portion of Ii was shown to diminish trimer formation and 
endosomal targeting [17-19]. Structural and biochemical evidence for direct 
interactions between the Ii CLIP region and the peptide-binding groove has also 
been reported [20-27], and this interaction has been suggested as a major contributor 
to formation of the Ii// complex.  Other sites of interaction between Ii and the / 
complex have been proposed to lie outside of this CLIP region [15, 28, 29].  Wilson 
and coworkers demonstrated that Ii could associate with Class II molecules in which 
the peptide binding groove was already occupied, supporting the presence of other 
Ii-Class II interaction sites [29].  Park and coworkers also reported a direct interaction 
between the C-terminal trimerization domain and MHCII molecules[15].  
The structural basis for MHC-II / complex formation and peptide binding 
has also been investigated by a wide variety of methods [30-35].  It has been shown 
that the N-terminal domains in both chains pack together in a manner closely 
resembling the packing in Class I MHC in order to stabilize formation of the 
heterodimer and engage the T-cell receptor (TCR).  These domains are highly 
polymorphic, and thus regulate the correct pairing of allelically-matched MHC-II 
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chains.  The peptide binding groove lies in the amino-terminal domain and is formed 
by antiparallel -sheets and antiparallel -helices, again closely resembling the 
arrangement in Class I MHC[30].  It has also been proposed that the  heterodimers 
have an affinity to form dimers themselves, and this dimer of dimers is thought to 
increase the affinity for the CD4 co-receptor as well as play a role in T-cell response 
by facilitating TCR crosslinking[30, 36].   
 The studies above, along with many others, have resulted in a strong structural 
understanding of the intracellular and extracellular regions of Ii and MHC-II proteins.  
However, the membrane-localized regions of the complex have also been strongly 
implicated in MHC-II assembly, transport and function for the past thirty years.  While 
these regions are inherently more challenging to characterize, they have been shown 
as sites of key protein-protein interactions involving the transmembrane domains of 
Ii, , and  Indeed, it is highly likely that transfer of conformational information 
from the transmembrane regions to the extracellular domains could be transmitted 
by the connecting peptides that link the two. Membrane-localized regions are also 
sites of critical protein-lipid interactions, as evidenced by the sensitivity of MHC-II 
protein conformation (and subsequent T-cell activation) to changes in membrane 
environment. The accumulated evidence that these regions are sites of critical 
interactions is compelling, and should not be ignored when considering the functional 
mechanisms of MHC-II.  This review describes work that forms the basis for our 
understanding of the role of the membrane and membrane-localized protein regions 
in assembly, transport and function of MHC-II. 
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II. Discussion 
 
IIA. Membrane spanning protein regions are key interaction sites for assembly 
of the MHC-II throughout its transport pathway  
 
Assembly and function of Ii is influenced by transmembrane domain interactions. 
 In 1999, Ashman and Miller reported the first evidence that the Ii 
transmembrane domain (TMD) is the site of critical protein-protein interactions that 
stabilize the functional Ii homotrimer [37].  This study demonstrated that residues 1-
80 of Ii, encompassing the N-terminal cytoplasmic and transmembrane domains (see 
Figure 1B), could support trimerization in the absence of the luminal “trimerization” 
domain.  In the same study, the role of the TMD was further explored by mutagenesis 
of a cluster of highly conserved polar amino acids(Gln47, Thr49, and Thr50, Figure 
1C) in the center of the TMD which, when simultaneously mutated to hydrophobic 
residues (specifically Ala or Ile), prevented trimerization of the full-length Ii both in 
vitro and in vivo.  This triple mutation also eliminated MHC-II binding to Ii, and thus 
prevented formation of the mature MHC-II complex and antigen presentation.  The 
lack of trimer formation for the hydrophobic mutant was surprising since the luminal 
“trimerization” domain, confirmed to form trimers in the absence of the cytoplasmic 
and TMD [16], was intact in this construct.  The authors suggested that disruption of 
the TMD interactions in vivo was likely altering the orientation of Ii with respect to 
the bilayer, either via tilting of the TMD to accommodate hydrophobic mismatch or 
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via membrane deformation. Such TMD rearrangement could then impact the 
orientation of the luminal domains of Ii with respect to one another, thus weakening 
(or preventing) interactions in the soluble trimerization domain. The authors also 
suggest that the ability of soluble, recombinant Ii to form trimers could reflect the 
high concentrations of the protein in these structural studies, typically in excess of 
100-1000-fold greater than the concentration of Ii in the ER.  Indeed, overexpression 
of their Ii TMD mutant to high concentration was able to rescue some degree of trimer 
formation, likely via alternative sites of interaction.  Therefore, while structural 
studies of soluble domains provide very useful data, we suggest that these studies do 
not rule out other domains (such as the TMD) as sites of critical interaction. 
 Ashman’s results were later expanded using biophysical and computational 
methods to determine the molecular basis of Ii TMD interactions.  In 2002, the TMD 
was investigated in isolation from the rest of the protein to probe the secondary 
structure of this region and propose a molecular model of its self-association[38].  In 
this study, Kukol and coworkers utilized Fourier transform infrared (FTIR) data 
obtained from 13C = 18O labeled TMD peptides in conjunction with molecular 
dynamics (MD) simulation to resolve the backbone structure of the Ii TMD helix and 
suggest potential sites of helix-helix interaction.  They presented a structure of the Ii 
TMD as a left-handed coiled-coil trimer stabilized by putative interhelical contacts 
involving Gln47 and Thr50, strongly supporting the work of Ashman and Miller 
described above [37].   In a separate study in 2006, we investigated the assembly and 
stoichiometry of the wild-type Ii TMD in a variety of detergent conditions [39].  This 
study provided the first experimental evidence that the predominant oligomeric state 
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for the Ii TMD is a trimer with a dissociation constant of approximately 120 nM in n-
dodecylphosphocholine (DPC) micelles. This low Kd suggests a very strong interaction 
and a clear bias toward Ii trimer formation, reflecting the biologically active 
oligomeric state of the full-length protein.  Indeed, such a low Kd is unsurprising given 
that in vivo cross-linking of full length Ii at physiologically relevant concentrations 
revealed almost exclusive formation of Ii trimers and no detectable concentration of 
either monomeric or dimeric Ii species [37].  In the same study, we measured the 
effects of point mutation of Gln47, Thr49, or Thr50 on Ii TMD helix-helix interactions 
in a natural membrane bilayer, demonstrating that these interactions were facilitated 
in large part through interhelical H-bonding of Gln47 and Thr50 [39]. Taken together, 
these studies support a model for MHCII complex assembly that accounts for strong 
and specific Ii TMD interactions that may (i) initiate trimer formation (Figure 2A) and 
(ii) direct the orientation of the luminal domains for optimal interaction. 
 While the studies mentioned above implicate the cluster of TMD polar 
residues in Ii trimer formation, MHC-II binding and antigen presentation, a 2001 
study presented conflicting data [40].  In this work, the entire C-terminal half of the Ii 
TMD (residues 42-53) was replaced with 12Ala residues, thus removing the cluster 
of polar residues altogether.  This substitution did not prevent ER translocation, Ii 
trimer formation, or association with Class II molecules.  Instead, the mutant Ii 
associated with Class II molecules more strongly than the wild-type protein, probably 
reflected in part by its increased resistance to proteolysis.  While these conflicting 
results are difficult to explain, one possible explanation may lie in the intermediate 
hydrophobicity of Ala which, in a mutant containing 12Ala residues, leads to a 
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marked increase in the predicted free energy of membrane insertion as compared to 
the wild-type sequence [41].  A subtle increase in the free energy of insertion may 
alter properties such as tilt angle or TMD length, while more significant increases in 
insertion free energy will prevent membrane insertion of a sequence altogether.  We 
suggest that the nature of the mutation in this work may substantially alter 
Iimembrane interactions and this may account for differences observed.      
 
Engagement of Ii with Class II molecules via TMD interactions 
 The polar residues in the Ii TMD that drive Ii trimer formation have also been 
reported to impact interactions between Ii and MHC-II molecules [37], and raise the 
question of whether the TMDs of all three proteins are sites of stabilizing interactions 
in the Ii-MHC-II complex (Figure 2B). In 2001, Castellino and coworkers [42] reported 
interaction between MHC-II and Ii regions outside of the CLIP domain in order to 
explain the efficient binding of the non-polymorphic Ii with a diverse range of MHC-
II molecules displaying large differences in affinity for the CLIP peptide.  In order to 
completely block possible interactions with CLIP, an antigenic peptide was covalently 
bound to the MHC  chain. Despite this, Ii was found to directly associate with MHC-
II in detergent micelles. Truncation mutants were used to locate the site of MHC-II-
binding within Ii, and it was traced to the TMD.  An Ii construct containing only 
residues 28-58, mapping to the TMD, was shown to stably associate with MHC-II via 
interactions that lay well outside of the CLIP region. Since then, others have also 
reported the stable binding of Ii to MHC-II molecules in vivo via interactions in its 
cytosolic and transmembrane domains[43].  For example, a membrane-proximal YFR 
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motif in the cytoplasmic tail of the MHC-II β chain has been shown to regulate the 
activity of the ER-retention motif in Ii, likely through direct protein-protein 
interactions, between the -chain and Ii. Expanding into a model that accounts for the 
above reports, we suggest that interactions localized to the TMDs of Ii and MHC-II 
molecules (either individually or as the preformed heterodimer) contribute to 
complex formation (Figure 2B), possibly even initiating complex formation whilst the 
CLIP and trimerization domains access their optimal binding arrangements.  Thus far, 
there have been no reports of the molecular details of this interaction, however in 
Figure 1C we have mapped the residues in the Ii TMD that lie on the same helical face 
as Q47 and T50 and are thus likely to be excluded from a Ii-MHC-II interaction. The 
remaining Ii TMD residues would be available to direct Ii-MHC-II interactions, but it 
remains to be determined which residues are involved.   
 
TMD interactions impact MHC-II assembly, conformation, transport, and peptide-
binding 
 In 1984, Travers and co-workers [44]were the first to report the potential role 
of the MHC  and  TMDs in MHC-II complex assembly and peptide binding.  In this 
study, it was shown that conserved Gly residues in the TMDs of both MHC-II antigens 
are spaced such that they would map to a discrete face of an -helix, occupying 
positions 1 and 4 in a heptad repeat pattern typical for -helical coiled coils (see 
Figure 3A).  A model was proposed in which helical MHC  and  TMDs packed 
together along these Gly-containing faces. In this model, a Cys residue near the N-
terminus of the  TMD also lies on this Gly-containing interface (Figures 3A-B).  This 
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Cys is very highly conserved, indeed it is invariant down to sharks [45] and is likely 
to play a key, yet currently unknown, role in Class II structure, function, or both. It has 
also been proposed that the  and TMDs are oriented by a salt bridge between a Glu 
residue in the  chain and a Lys in the  chain[44, 46], as shown in Figures 3A-B. 
However the Glu residue in the  chain is not conserved outside of mammals [45]. 
One hypothesis is that, in complexes missing this Glu, the interaction could be rescued 
via polar interaction involving the invariant Cys. 
 In 1992, Cosson and Bonifacino replaced the TMD in each MHC-II protein with 
that from the interleukin-2 receptor [46].  The resulting chimeras assembled 
incorrectly in COS cells, failing to bind conformation-dependent antibodies (i.e. 
antibodies that recognize only appropriately folded conformers of class II molecules) 
and being largely retained in the ER.  In addition to replacing the entire TMD, mutants 
were constructed in which Gly residues present in both the MHC  and TMDs 
(Figure 3A) were collectively replaced with Val residues.  This was one of the earliest 
reports experimentally demonstrating the role of the GXXXG motif, a now well-
accepted helix-helix interaction motif [47-49], in stabilizing interactions between  
and  TMDs. Removing the TMD Gly residues had the same impact as replacing the 
entire TMD with that of an unrelated protein: the chains were unable to bind 
conformational antibodies and were retained in the ER. It was also shown that the 
MHC  and  TMDs could drive association of other protein sequences into which they 
were grafted.  This study supported the model first proposed by Travers and co-
workers [44] and was a pioneering example of how the TMDs of MHC-II proteins 
could impact assembly and transport of the full-length protein. Subsequent reports 
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strengthened this conclusion, demonstrating that other types of changes to MHC-II 
TMD sequences also result in dysregulation of transport in vivo (although there have 
been reports contesting the role of the TMDs as well [50]). Truncation of the MHC  
and  chains to remove the cytoplasmic domains of both proteins and the C-terminus 
of the MHC  TMD lead to a large reduction of MHC-II expression on the plasma 
membrane [51].  Replacement of the MHC TMD with that of the  chain lead to 
accumulation of MHC-II molecules in the early- and late-endocytic 
compartments[52].  In both studies, this impaired transport was not due to lack of 
association of Ii, as immunoblotting indicated Ii binding to mutant complexes (likely 
via interactions in the CLIP and luminal domains which were intact in all constructs 
tested).  The changes in the TMD were instead thought to impact the global MHC-II 
conformation, leading to a transport-impaired conformation.      
 Sherman and coworkers also reported the far-reaching influence of  and  
TMD interactions on MHC-II conformation in their investigation of the impact of pH 
on peptide binding of purified versus membrane-bound MHC-II [53].  While purified, 
detergent solubilized MHC-II showed very little sensitivity to pH with regards to 
structural stability and peptide-binding properties, membrane-bound MHC-II on the 
cell’s surface demonstrated large fluctuations in peptide binding with changes in pH.  
The results were attributed to the influence of TMD-lipid bilayer interactions on the 
conformation and/or flexibility of the N-terminal domains, which then modulated 
peptide binding. Although the nature of these conformational changes remains to be 
characterized in full, this study provides clear evidence that truncated, soluble class 
II proteins can show markedly different behavior to their membrane-bound (and 
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more physiologically-relevant) counterparts, and studies in which the membrane-
localized proximal regions are deleted should be interpreted with caution. 
 The majority of work implicating MHC-II TMDs has been performed in vivo on 
full-length proteins.  More recently, we have demonstrated in vitro that the TMDs of 
MHC-II molecules in isolation have a strong propensity to associate into homodimers 
and / heterodimers in both model and natural membranes [54].  The results from 
this study indicated that interactions between the  and  TMDs are strong and 
sequence-dependent, and validate the role of transmembrane Gly residues first 
suggested 26 years earlier by Travers and co-workers [44].  Our study also revealed, 
via mutagenesis and computational modeling, that there are two likely modes of 
interaction between the  and  TMDs involving different Gly packing arrangements.  
The two Gly packing arrangements involved pairing of the single GXXXG motif in 
the  TMD (indicated by a bracket in Figure 3A) with either of two available GXXXG 
motifs in the  TMD.  The mutants from this work were introduced into the  and  
TMDs of mouse class II molecules, followed by in vivo measurement of MHC-II 
conformation and membrane localization in HEK293T cells [55].  The results revealed 
that the differential pairing of the GXXXG motifs directed the formation of two 
distinct MHC-II conformers (Figure 3B) in the ER, most likely under the guidance of 
Ii..  Pairing of the sole GXXXG motif with the C-terminal GXXXG motif in the  
TMD yielded a more robust interaction, but resulted in a MHC-II conformer that 
displayed weak T cell activation.  Pairing via the N-terminal GXXXG motif in the  
TMD lead to formation of an I-Ak MHC-II conformer, Ia.2+, previously shown to 
localize to lipid rafts, control B-cell calcium signaling, and enhance antigen 
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presentation to T cells [56, 57].  Lipid raft localization may be further facilitated by 
palmitoylation of the invariant Cys residue in the MHC-II -chain, shown in Figure 3.  
Palmitoylation of transmembrane and juxtamembrane Cys residues has been 
reported as a lipid raft-targeting mechanism for integral membrane proteins [58], 
and this has been demonstrated for I-A and HLA-DR complexes [59, 60].  
The above studies present highly compatible models of the TMD interactions 
in MHC-II, whereby Gly residues pack together (either as discrete G-XXX-G motifs or 
as part of heptad repeat motifs) to stabilize complex formation.  Indeed, a recent 
review highlighted known disease-associated MHC-II polymorphisms that target 
these Gly-rich helical TMD faces, and thus may significantly impair protein 
interactions and destabilize MHC-II complexes [61]. These complexes may be 
localized to specific membrane microdomains by palmitoylation of the highly-
conserved Cys residue present at the transmembrane / connecting-peptide interface 
in the  chain.  Recently, the MHC-II Ii.2+ conformer has also been shown to interact 
selectively with antigen-B cell receptor (BCR) complexes, becoming selectively 
loaded with BCR-derived peptide antigen prior to its expression on the cell’s surface 
[62], and these interactions are thought to involve the TMDs of MHC-II and the BCR.  
MHC-II TMDs have also been implicated in interactions with MARCH family ubiquitin 
ligases [63] and tetraspanin proteins including CD82 [64-66] , however the molecular 
determinants of those interactions have yet to be determined.   
Taken together, the work described above demonstrates the strength and 
influence of TMD interactions in functional assembly of the MHC-II heterodimer, and 
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this has now been accounted for in the extended model we propose here for MHC-II 
assembly (see Figure 2C). 
 
 
IIB. Membrane composition and membrane lipid environment impact MHC-II 
localization, conformation and function 
Lipid Rafts and localization of MHC-II protein.   
 In addition to membrane-localized protein interactions, there is much 
evidence that the MHC-II is regulated by the properties of the membrane.  The cell 
membrane of mammalian nucleated cells contains a variety of biological molecules, 
notably lipids (glycolipids, sphingolipids and cholesterol) and proteins.  A dynamic 
clustering of sphingolipids and cholesterol allows the formation of specialized 
structures in the membrane known as  “rafts” which are approximately 4-200 nm in 
diameter [67]. Biochemically, rafts are loosely defined as detergent resistant 
membrane microdomains based on their relative insolubility in mild non-ionic 
detergents at low temperature [68], although there is some controversy about their 
nature in in vivo conditions [69]. A number of membrane proteins are proposed to 
associate specifically with lipid rafts. Treatment of cells with cholesterolbinding 
pharmacological mediators perturbs the raft assembly and disperses raft associated 
proteins [70]. Several studies also demonstrate that a substantial fraction of MHC-II 
proteins are raft-associated, however the relative percentage of raft-associated 
protein reported in the literature ranges from roughly 50%  [71] down to 10-20% 
[56, 72].  
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Importance of rafts in MHC-IIrestricted T-cell activation 
 Stimulation of T-cells by antigenic peptides presented in the context of MHC-
II molecules requires a stable contact between T-cells and antigen presenting cells 
(APCs) for effective T-cell activation [73]. Lipid rafts in the outer leaﬂet of the 
membrane bilayer induce clustering of the peptide-MHC-II (p-MHCII) complex on the 
APC surface to increase the surface density of the p-MHCII, resulting in appropriate 
T-cell activation [74-76]. Disruption of lipid rafts by sequestration of cholesterol after 
treatment of APCs with methyl-β-cyclodextrin impaired the presentation of p-MHCII 
complexes to T-cells [74]. However, such defects could be reversed at high cognate 
peptide concentrations, indicating that lipid rafts indeed play an important role in 
enhancing the T cell response at low ligand concentrations [77].  
 
MHC-II TMD interacts with membrane cholesterol 
 Direct interactions between membrane cholesterol and membrane-embedded 
protein regions can impact the biological function of membrane bound receptors such 
as cholecystokinin (type B), oxytocin, and nicotinic acetylcholine [78]. The nicotinic 
acetylcholine receptor has been shown to have internal sites capable of forming 
adducts with cholesterol, resulting in stabilization of the protein’s structure [79]. 
These proteins bind cholesterol via a range of cholesterol binding sequence motifs 
found within their TMDs. The cholesterol recognition/interaction amino acid 
consensus sequence, generally referred as the CRAC motif, is a short, linear sequence 
that can be depicted as (L/V)-X1−5-(Y)-X1−5-(K/R).  This motif is composed of a 
branched apolar Leu or Val residue, followed by a segment containing 1–5 of any 
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residues, an aromatic Y residue, a second segment containing 1–5 of any residue, and 
finally a basic Lys or Arg residue. The CARC motif, thus far only described for the 
human nicotinic acetylcholine receptor, is an inverted CRAC motif with the consensus 
sequence (K/R)X1–5(Y/F)X1–5(L/V).  In the CCM (cholesterol consensus motif) [80] 
the amino acids interacting with cholesterol are not a linear sequence motif, but are 
distributed between TMDs within polytopic membrane proteins. One helical TMD 
contains the sequence motif (W/Y)(I/V/L)(K/R), whereby all residues must face the 
same side of the helix. In addition, another aromatic amino acid, either phenylalanine 
or tyrosine, is needed on a second helix to bind cholesterol from the other side. Both 
oxytocin and serotonin 1A receptors contain a strict cholesterol consensus motif 
(CCM), and in both there is a dramatic increase in agonist affinity in the presence of 
cholesterol [81, 82].  As highlighted in Figure 3A, analysis of the amino acid sequences 
of the mouse MHC-II TMDs revealed a putative CRAC-like motif at the C-terminus of 
the TMD[I/V -(X) 4 -F  -(X) 5 -R ]. Similarly, an overlapping CRAC/CCM-like motif [F 
-(X) 2 -L  -(X) 2 -F -(X) 1,3 -R  /R] was observed in the mouse MHC-II  β TMD [83].  
Comparison of these sequences to those from human and rat MHC-II suggests that 
these motifs are largely conserved in the TMD and juxtamembrane regions (Figure 
3A). WhilePhe residues in both TMDs proposed to contribute to cholesterol-binding 
motifs are arranged on the same helical face as the G-XXX-G motifs (Figure 3B), and 
may be blocked from forming interactions with cholesterol upon tight helix-helix 
interactions, , several of the remaining residues map to the opposite helical face and 
would thus be exposed to the lipid membrane and available for binding of cholesterol.  
These residues are similar for both TMDs and are shown for human HLA-DRA1 and 
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HLA-DRB1 in Figure 3B. It is also interesting to note that these motifs are accessible 
for cholesterol binding in both MHC-II conformers shown in Figure 3B, although the 
motif in the TMD would likely be displaced outside the bilayer and this may impact 
the binding affinity. 
 To investigate whether these motifs in the MHC  and  TMDs directed binding 
of cholesterol, we used a synthetic peptide construct derived from residues T219-
L244 of MHC α chain and residues M227-I247 of MHC β chain coupled together using 
Ala-Lys as linkers [83]. Interaction of cholesterol with the synthetic MHC-II TMD was 
monitored by changes in the fluorescence emission spectrum of 22-NBD-cholesterol, 
a common fluorescent sterol analog. In the presence of the MHC-II TMD synthetic 
construct, the fluorescence emission spectrum of NBD-cholesterol underwent a large 
increase in the intensity of the emission peak, coupled with a blue shift of 40 nm for 
the emission maximum, indicative of binding of the sterol in a hydrophobic pocket.  
Cholesterol-dependent conformational changes in the MHC-II TMDs were also 
monitored using circular dichroism, and revealed that the helical content of the 
liposome-reconstituted TMDs decreased significantly (from 84% to 68%) in the 
presence of cholesterol.  This result suggests that the binding of cholesterol may 
unwind the alpha-helical coiled coil formed between the  and TMDs, allowing 
access to the Phe residues on the same helical face as the G-XXX-G motifs and sliding 
of the two TMDs along one another to stabilize an alternative conformation (for 
example, Ia.2- vs. Ia.2+ as shown in Figure 3B).  This model would be in keeping with 
the fact that mutation of cholesterol binding residues F240, L243, and F246 in the 
MHC-II TMD also decreased the affinity for cholesterol [83].  These binding and 
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structural studies clearly demonstrated that cholesterol interacts with the MHC-II 
TMD and alters its conformation [83].  
The question still remains as to how a cholesterol induced conformational 
change in the MHC-II TMD dictates overall conformation of the MHC-II protein in the 
environment of membrane, and how such changes influence the immune response. 
At this stage, the relative stabilities of the various MHC-II conformers in the presence 
and absence of membrane cholesterol remains unknown. 
 
Impaired MHC-II restricted T-cell activation in a disease model: Role of membrane 
cholesterol  
 We recently reported an unrecognized functional role for MHC-II in the 
context of membrane lipid environment in a specific disease model, namely visceral 
leishmaniasis, in which lipid metabolism is altered at the active stage of the disease.  
Visceral leishmaniasis is caused by the protozoan parasite Leishmania donovani (LD) 
which replicates within macrophages and dendritic cells [84]. The disease is 
characterized by immune suppression [84], hypocholesterolaemia [85-87] and 
increased fluidity of infected host cells [77]. Restoration of membrane cholesterol by 
liposomal cholesterol injection in infected animal models allows expansion of anti-
leishmanial T-cells [87] and, interestingly, hypercholesterolaemic mice are solidly 
protected against lethal challenge of LD infection [88]. During their intracellular life 
cycle, parasites take up membrane cholesterol which increases membrane fluidity 
[77].  LD-infected splenic macrophages (LD-macrophage), dendritic cells and/or cells 
of the monocyte macrophage lineages P388D1 (LD-P388D1) failed to activate T cells 
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in response to a low dose of exogenous peptide [77]. We also showed that in infected 
macrophages there is an increase in lateral mobility of membrane proteins [89]; such 
macrophages are incapable of forming an effective immunological synapse with 
antigen specific T-cells [90].  
 The distribution of MHC-II protein (Ad) in leishmania infected macrophages 
was studied to see how an intracellular protozoan parasite like leishmania modulates 
distribution of MHC-II protein on the cell surface. This was studied in vitro by 
infecting the monocyte-macrophage cell line (P388D1) with leishmania parasites, 
and following the intracellular growth as a function of time using microscopy 
methods. The raft architecture of uninfected P388D1, LD-infected (LD-P388D1) and 
cholesterol liposomes treated LD-infected P388D1 was studied using raft [CD48 and 
choleratoxin-B (CTX-B)] and non-raft (CD71)-specific antibodies. Colocalization of 
CD48/CTX-B and CD71 with raft and non-raft associated MHCII indicated how the 
distribution of MHCII varied under parasitized conditions and upon treatment of LD 
infected P388D1cells with liposomal cholesterol.  Binding of anti-CD48 monoclonal 
antibody (mAb) and CTX-B subunit decreased significantly in LD-P388D1 and, 
consequently, colocalization with Ad was not observed, but this was restored in 
liposomal cholesterol treated LD-P388D1 cells63. Conversely, colocalization between 
Ad and CD71 remained unaffected regardless of the presence or absence of 
intracellular LD parasites. Furthermore, uninfected  P388D1 and  liposome 
cholesterol treated LD-P388D1, but not LD-P388D1 itself, formed a peptide-
dependent synapse with T cells quite efficiently, and this result was supported by 
intracellular Ca2+ mobilization in T cells and IL-2 production [77].  
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 By exploiting biophysical techniques like surface plasmon resonance 
spectroscopy (SPR), we determined the kinetic parameters of peptide MHC stability.  
In this regard p-MHCII complex formation was studied with a limiting concentration 
of peptide by SPR, while p-MHCII complex formation on the isolated membrane was 
studied in real time, as described by others [91, 92]. Increasing concentrations of 
OVA323-339 (Ad restricted peptide) were flowed over an immobilized membrane on an 
L1 chip, and kon and koff rates were determined using a Langmuir 1:1 binding 
isotherm. It was observed that kon and koff values were 67.3 ms-1 and 9.32 ms-1, 
respectively, for normal macrophage membrane, but 5.6 ms-1 and 32.2 ms-1, 
respectively, for LD-macrophage membranes [93]. This observation indicated that p–
MHCII complex formation is compromised in LD-macrophages compared with 
normal macrophages. This observation has important implications in the 
immunobiology of visceral leishmaniasis, as patients at the active stage of the disease 
are immunosuppressed. This may be due to faster dissociation of cognate peptide 
from the peptide-MHC-II complex leading to a defective anti-leishmanial T-cell 
response.  
 
Cholesterol driven conformational changes within MHC-II proteins 
 Conformational changes within MHC-II during biosynthesis, folding, and in the 
MHC-II-containing compartment were detected by mAb binding [94-96], which is a 
powerful tool for this type of study. The 11-5.2 anti-Ak-mAb recognizes the Ia.2 
epitope on Ak MHC-II, defined as a lipid raft resident MHC-II conformer vital to the 
initiation of restricted B cell-T-cell activation [94].   Binding of an anti-Ia.2 mAb, such 
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as 11-5.2, is highly dependent on the residues Arg57 and Gln75 of the Ak chain, 
residues near the peptide binding groove [56]. Depletion of membrane cholesterol 
from APCs by methyl-β-cyclodextrin treatment compromised peptide-MHC-II 
formation coupled with impaired binding of conformational antibody 11.5-2 [83]. 
The reduced binding of 11.5-2 to Ia2 epitope Ak could be corrected by restoring 
membrane cholesterol. Thus membrane cholesterol appears to play an important role 
in maintaining the active form of MHC-II [83]. 
 Following on from our study demonstrating the interaction of MHC-II TMDs 
with membrane cholesterol via a CRAC-like motif, which brought about a 
conformational change in the protein [83], we also investigated how interaction of 
cholesterol with the TMD influences conformational changes in the distal peptide 
binding groove of MHC-II. The availability of conformationally and non-
conformationally specific anti Ak mAb greatly aided our investigation. We showed 
that binding of 11–5.2 to LD infected macrophages (I-MΦ) was reduced by about 60% 
as compared to normal macrophages (N-MΦ), whereas binding of 10–2.16 were 
comparable.  The mAb 10-2.16 recognizes the β-chain of Ak, specifically Ia.17. This 
observation indicated that Ak molecules are located on the surface of I-MΦ, where 
conformational constrains may limit the binding of 11–5.2 to I-MΦ when they are not 
treated with liposomal cholesterol. This effect was cholesterol-specific because the 
binding of 11–5.2 with I-MΦ was not restored by cholesterol analogue liposomes 
(made from 4-cholesten-3-one lacking the OH function of cholesterol) or 1,2 
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) liposome treatment [87, 90].  
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We used this analogue because the alignment of cholesterol in the membrane 
is thought to be supported by a hydrogen bond between the cholesterol OH group and 
the amide bond of sphingolipid [97] and this interaction is presumably not present in 
the case of this analogue because of the lack of an OH group. To study the importance 
of cholesterol binding at the appropriate motif on the distal peptide binding groove 
of MHCII, we mutated putative cholesterol binding residues (F240, L243, and F246 of 
the β chain) in the TM domain of full-length MHCII (mutant Ak) and its effects on the 
nature of the peptide binding groove was monitored using binding of conformation-
specific mAb and T cell stimulating ability. CHO cells were transfected with either Ak 
or mutant Ak, which were used as APCs. The binding of conformation-specific 
antibody was assessed using mAb 11-5.2 and total cell surface expression was 
assessed using nonconformational antibody (10-3.6). Our study showed that the cell 
surface expression of MHCII remains unaltered in mutant Ak whereas binding of 
conformational antibody was reduced by ∼5-fold as compared with CHO cells 
expressing wild-type MHCII. The ability of transfected cells to stimulate T cells was 
assayed in terms of IL-2 production in the presence of HEL46-61 peptide. It was 
observed that mutant Ak showed compromised ability to stimulate T cell hybridoma 
(HyH12.6, Ak restricted) as evident from the decreased IL-2 production as compared 
with wild-type Ak. This supports the hypothesis that interaction of cholesterol with 
the CRAC motif is important to bring about proper conformational orientation. 
Transfection of CHO cells with wild-type full length MHC-II, but not with  mutant 
MHC-II, activated antigen-specific T cells and decreased the binding of conformation-
specific antibodies [83]. Thus, cholesterol-induced conformational changes within 
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the MHC-II TMD may allosterically modulate the peptide binding groove, leading to T 
cell activation. 
 
Analysis of MHC-II-cholesterol interactions by Molecular Dynamics (MD). 
 It has been shown through MD simulation studies that cholesterol interacts 
with the membrane proximal regions of rhodopsin to induce local structural 
perturbation, which in turn brings global conformational rearrangements through 
rigid body motion [98]. We performed exhaustive MD simulations to study the effect 
of cholesterol binding on the structures of the MHC-II TMD, the peptide binding 
groove, and the protein region linking these two  [99]. The results revealed marked 
variations in flexibility and conformational adaptability of the MHC-II proteins in 
response to cholesterol binding. Removal of cholesterol from the complex increased 
the rates of fluctuation of residues along both chains of MHC-II, including those in the 
peptide binding domain (PBD).  Structural alterations in the PBD might lead to loss of 
peptide binding and/or presentation of peptide to T-cells.  Calculation of the solvation 
free energies (Kcal Mol-1) of the PBD and the bound peptide for a few selected 
ensemble structures extracted at various time points of the simulation in the 
presence and absence of bound cholesterol showed significant reductions in energies 
for most of the complexes in absence of bound cholesterol, indicating that stability of 
the peptide-MHC-II complex may decrease in the absence of cholesterol (Figure 4).   
 The MD results provided insight into the mechanistic details of possible long 
range allosteric adaptation observed for the MHC-II extracellular domain upon 
cholesterol binding to the TMD. Cross-correlation of flexibility analyses suggest that 
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changes at the MHC-II TMD are correlated with conformational variation at the PBD 
[99]. To test the prediction that peptide-MHCII stability is compromised in the 
absence of cholesterol, we measured kinetic stability on the cell surface. These studies 
made it clear that the rates of dissociation of the cognate peptide from the complex 
were 1.45, 16.3, and 1.68 μs-1, respectively, in normal macrophages, infected 
macrophages, and liposomal cholesterol treated infected macrophages. This was 
further validated by the progressive decrease in IL-2 production in anti-LACK 
(Leishmania homolog for the receptor of activated C Kinase) T-cells noted as a 
function of time. This observation shows a clear association between reduced binding 
of 11–5.2 to cell surface Ak and faster dissociation of the cognate peptide from p-MHC-
II complex in infected macrophages. The above defects were found to be corrected by 
liposomal cholesterol treatment of LD-macrophage [93]. On the basis of our 
computational data coupled with experimental findings, we suggest that the 
interactions of cholesterol with the MHC-II TMDs may allosterically modify the 
conformation of the peptide binding groove leading to more stabilization of the p-
MHC-II complex on the cell surface.  MD based studies involving serotonin 1A [100, 
101] and β2 adrenergic receptors [102] have shown that enrichment of cholesterol 
within the membrane alters protein oligomerization and stability.  
 The modulation of cholesterol-induced conformational changes in membrane 
proteins is complex, and to our knowledge there are no simple methods by which to 
monitor the nature of changes that alter agonist affinity. However, we were able to 
show that the reduced p-MHCII stability in cholesterol depleted APCs was restored to 
normal levels by liposomal cholesterol treatment. Our results bring forth a 
28 
 
mechanistic view to explain how decreased membrane cholesterol in LD-
macrophages or in cholesterol depleted APCs may influence conformation and 
downstream function of MHC-II. Thus liposomal cholesterol may be used as an 
adjunct with chemotherapy to reduce the dose of chemotherapy required for 
treatment of visceral leishmaniasis.   
To our knowledge, the conformational change of MHC-II in a disease-like 
condition has only been reported for visceral leishmaniasis, however there are a 
number of studies that indicate that high cholesterol may protect from infectious 
diseases [103].  High cholesterol has been linked to protection against a variety of 
parasitic infections [104] and may have other beneficial effects on the immune 
system, as suggested in a report showing that hypocholesterolaemic men had 
significantly fewer circulating lymphocytes, total T cells, helper T-cells and CD8+ cells 
than hypercholesterolaemic men [105]. Conversely, low levels of cholesterol in 
critically ill surgical patients have been reported to correlate inversely with 
concentrations of IL-6, soluble IL-2 receptor and IL-10 [106].  Furthermore, thymic 
development of immune repertoire is dependent on cholesterol, as the disruption of 
the lipid rafts of thymic epithelial cells impairs CD4 +T-cells expansion [60].   
 
III. Conclusions 
 The studies summarized above emphasize the importance of protein-protein 
and protein-lipid interactions involving the membrane-localized protein regions of 
the MHC-II, and demonstrate that models of this critical immune receptor should take 
these regions into account.  It has been shown that the TMDs of MHC  and 
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invariant chain are the sites of strong and selective interactions that direct correct 
assembly, transport and function of the complex.  These interactions are driven, in 
part, by well-known TMD helix-helix interaction motifs (e.g. the GXXXG motif and 
motifs of polar residues) shown to impact the folding of a large number of integral 
membrane proteins.  Modification of the TMD sequences of either of the MHC-II 
proteins or chaperones (e.g. Ii) has been shown to impact assembly and dysregulate 
transport, leading to retention of the complex in the ER and thus preventing 
formation of the mature MHC-II required for antigen presentation.  We propose that 
TMD regions are therefore fundamental to the correct function of this immune 
receptor, and have integrated TMD interactions into the model of MHC-II assembly 
shown in Figure 2.   
 Interactions between the TMDs of the MHC-II chains and the membrane have 
also been shown to impact function.  The MHC-II protein needs to be associated with 
membrane microdomains enriched in sphingolipids and cholesterol (i.e lipid rafts) to 
induce T-cell activation at a limiting cognate antigen concentration.  Both the MHC  
and  chain TMDs contain sequence motifs known to direct the binding of membrane 
cholesterol (Figure 3A) and we have summarized work that clearly links the presence 
of cholesterol to maintenance of the correct MHC-II conformation.  This apparent 
requirement for membrane cholesterol may be exploited by the prozoan parasite 
Leishmania donovani, which takes up membrane cholesterol leading to increased 
membrane fluidity and disruption of membrane rafts. This reduction of membrane 
cholesterol also causes conformational changes within MHC-II that lead to decreased 
affinity of cognate antigen, thus contributing to the defective MHC-II restricted T-cell 
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activation observed in leishmaniasis. Such defects can be corrected by liposomal 
delivery of cholesterol in leishmania-infected macrophages, indeed liposomal 
cholesterol treatment offers protection in infected hamsters. This real world example 
of how a parasite (leishmania) exploits membrane-localized interactions of MHC-II to 
dampen the hosts’ immune response may represent a general strategy of immune 
system evasion, and underpins the importance of recognizing these regions in any 
description of MHC-II biology.   
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Figure Legends 
Figure 1. Current Models of Class II MHC (MHC-II). A. In the classical model of Class 
II assemblyin the endoplasmic reticulum (ER), trimers of MHCII-associated invariant 
chain (Ii) bind three MHC-II alpha/beta heterodimers () to form a nine-chain Ii3 
(3 complex stabilized by interactions between the CLIP (class-II-associated 
invariant chain peptide) region in Ii and the MHC-II peptide binding cleft. B. An 
alternative model has also been reported in which each Ii trimer binds a single 
heterodimer to form a Ii3 pentamer.  Also shown are the residues thought to 
form the boundaries of the N-terminal cytoplasmic, transmembrane, CLIP and 
trimerization domains of Ii. C. Sequence alignment of the transmembrane domains of 
the MHC-II invariant chain (CD74) for human, mouse and rat proteins.  The 
transmembrane domain sequence is underlined, and the highly conserved polar 
amino acids Gln47, Thr49, and Thr50 are shown in bold.  The transmembrane 
domains residues thought to stabilize the Ii trimer are highlighted using asterisks.   
 
Figure 2. Extended model for MHC-II assembly, accounting for contributions of 
transmembrane regions.  A. Previous data suggest that the strong and specific 
interactions observed between Ii TMDs may initiate Ii trimer formation and direct 
optimal orientation of the luminal domains. B. Although not reported to date, similar 
interactions between the TMDs of Ii and MHC-II molecules may also contribute to 
complex formation. C. Such interactions have also been observed between the TMDs 
of MHC  and chains, and mutation of TMD residues involved in these interactions 
has been shown to impact MHC-II function.   
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Figure 3. Transmembrane helixinteraction and cholesterol binding motifs in 
MHC-II TMDs lead to different conformations.  A. Alignment of the putative TMD 
sequences of human, mouse and rat MHC-II  and  chains, with corresponding 
sequence IDs and residue numbers given.  In each sequence, the TMD is underlined, 
whilst additional C-terminal juxtamembrane residues are also shown.  Conserved 
GXXXG helix-helix interaction motifs in both chains are highlighted in light gray, 
and conserved cholesterol-recognition motifs are shown in bold. B. The differential 
pairing of GXXXG motifs in the  and  chains (shown as Gly residues linked via a 
bracket) is proposed to give rise to two distinct MHC-II conformers, residing in 
different membrane environments and having differing abilities to stimulate T-cells.  
The relative position of residues within the cholesterol-recognition motifs in the helix 
is also shown. 
 
Figure 4.  Cholesterol binding to the MHC-II TMDs may destabilize peptide 
binding.  Computational and experimental evidence suggest that the stability of 
peptide-MHC-II complexes decreases in the absence of membrane cholesterol, 
possibly through direct interactions between cholesterol and TMDs.  This is thought 
to occur through cholesterol-induced conformational changes in the MHC-II TMD that 
allosterically modulate the peptide binding groove, leading to optimal peptide 
binding and downstream T cell activation.  
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